Palvella Therapeutics PVLA
NASDAQ PVLA
$157.24 +1.77 (+1.14%)
As of: Sep 4, 2026 · 3:59 PM EDT

Palvella Therapeutics (PVLA) EBIT Margin Growth (3y) (2017 - 2024)

Analysis

Palvella Therapeutics (PVLA) EBIT Margin Growth (3y) (2017 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -377.00
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -204.00
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 7,045.00
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -1,934.00
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 7,261.00
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 9,003.00
8 Royalty Pharma 28.45 Bn 27.61 Bn - -2,649.00
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 30,461.00
10 Palvella Therapeutics 2.24 Bn 1.93 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 -327,995.00
Dec 31, 2023 169,170.00
Sep 30, 2023 38,181.00
Jun 30, 2023 5,166.00
Mar 31, 2023 -74,261.00
Dec 31, 2022 -18,934.00
Sep 30, 2022 -20,733.00
Jun 30, 2022 -10,405.00
Mar 31, 2022 5,832.00
Dec 31, 2021 197,773.00
Sep 30, 2021 -37,511.00
Jun 30, 2021 -49,104.00
Mar 31, 2021 15,704.00
Dec 31, 2020 -69,696.00
Sep 30, 2020 -31,028.00
Jun 30, 2020 38,446.00
Mar 31, 2020 56,705.00
Dec 31, 2019 22,721.00
Sep 30, 2019 76,774.00
Jun 30, 2019 31,082.00